What is Maxis AI—and why is it redefining the future of clinical trials?

In this episode, we explore the rise of Agentic AI and how Maxis AI is pioneering its application in clinical research. Join Nicole Powell, Senior Vice President at Maxis AI, and Moulik Shah, CEO & Founder of Maxis AI, as they answer the most frequently asked questions from clinical operations, data management, and R&D teams.

Discover how AI agents—built for purpose and powered by context—are enabling trial teams to go beyond traditional automation, with intelligent systems that adapt, prioritize, and act across a robust clinical data ecosystem.

Whether you are evaluating where to start or looking to scale AI across studies and therapeutic areas, this episode offers actionable insights grounded in real-world experience.

Key Takeaways:

• What is Agentic AI and how it differs from traditional automation and generative AI.
• What sets Maxis AI’s AI agents apart—thanks to its end-to-end platform, industry experience, and early AI adoption (pre-COVID).
• Debunking common myths: AI bias, lack of human oversight, explainability, and misconceptions about scalability.
• Top challenges in scaling AI agents across therapeutic areas—and how a strong data foundation makes it possible.
• Where clinical teams should start the AI journey and what realistic adoption timelines look like.

🎧 Tune in to uncover how your team can lead the way in AI-driven clinical transformation—one smart step at a time.